HEMO
NEUTRALHemogenyx Pharmaceuticals Announces AGM Details
The biopharmaceutical company has announced details for its upcoming Annual General Meeting.
Hemogenyx Pharmaceuticals
183.50GBX
-0.14%
Market Cap
7.52M
Volume
14
0% of avg
P/E Ratio
EPS (TTM)
Beta
0.57
Day Range
0.00p - 0.00p
52 Week Range
0.00p183.50p1,200.00p
183.50p
Upcoming Events
HEMO
NEUTRALHemogenyx Pharmaceuticals Treats Second Patient with HG-CT-1 CAR-T Therapy
The biotechnology company has successfully treated a second patient as part of its ongoing Phase I clinical trial for its HG-CT-1 CAR-T therapy, a potential treatment for relapsed or refractory acute myeloid leukemia.
HEMO
BADHemogenyx Pharmaceuticals Advances to Clinical Trials Amid Financial Challenges
The clinical-stage biotechnology firm has progressed to Phase I trials for its lead product, but faces significant financial challenges with a rapidly diminishing cash position and ongoing losses.
HEMO
NEUTRALHemogenyx Pharmaceuticals Files Annual IND Report with FDA for AML Therapy
The biotechnology company has submitted its annual report to the FDA on its investigational new drug application for a CAR-T therapy to treat acute myeloid leukemia.
HEMO
NEUTRALHemogenyx Pharmaceuticals Provides Update on First Patient Treated with HG-CT-1 CAR-T Therapy
The biotechnology company reports the successful treatment of the first patient with its HG-CT-1 CAR-T therapy, with no adverse effects observed.
HEMO
NEUTRALHemogenyx Pharmaceuticals Recruits Second Patient for Clinical Trial
The biotechnology company has recruited the second patient for its clinical trial of a proprietary CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia.
HEMO
NEUTRALHemogenyx Pharmaceuticals Converts Convertible Loan Notes
The biotechnology company has converted its convertible loan notes into ordinary shares, simplifying its capital structure.
HEMO
BADHemogenyx Pharmaceuticals raises £709,200 through discounted share placing
The biotechnology company has raised £709,200 through a discounted share placing, signaling potential financial distress.
HEMO
GOODHemogenyx Pharmaceuticals Achieves Milestone with First-in-Human Treatment of HG-CT-1 for Relapsed or Refractory AML
The biotechnology company has achieved a major milestone by administering the first-in-human dose of its proprietary CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia.
HEMO
NEUTRALHemogenyx Pharmaceuticals raises £285,000 through convertible loan notes
The biotechnology company has raised £285,000 through the issue of convertible loan notes to support its clinical trial, but faces potential delays and challenges.